Iovance reports November 5, 2026 results for Iovance Biotherapeutics stock

Published on 10/17/2026 at 20:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter 2026 revenue reached USD 99.31 million. Iovance Biotherapeutics stock was last at USD 13.62 on October 16, 2026, down 7.47 percent on Nasdaq.

Results date and revenue

Iovance Biotherapeutics is scheduled to report third-quarter results on November 5, 2026.
Second-quarter 2026 revenue reached USD 99.31 million, up 65.7 percent year over year.
Iovance Biotherapeutics stock was last at USD 13.62 on October 16, 2026 at 4:00 p.m. ET, down 7.47 percent on Nasdaq.
Market capitalization stood at USD 6.2 billion as of October 16, 2026.

IOVA, US4622601007, Illustration mit AI erstellt.

Iovance Biotherapeutics is scheduled to report its third-quarter 2026 results on November 5, 2026, according to The Wall Street Journal. On Nasdaq, Iovance was last at USD 13.62 on October 16, 2026 at 4:00 p.m. ET, down 7.47 percent versus the prior close.

Revenue sets the next benchmark

For the second quarter of 2026, revenue reached USD 99.31 million, up 65.7 percent from the year-ago quarter, while adjusted loss per share was USD 0.11, according to MarketBeat. The upcoming report will give investors a fresh operating checkpoint against that revenue base.

Stock stays below its yearly high

The October 16 Nasdaq session covered USD 13.52 to USD 14.69, while volume reached 12,155,046 shares against an average of 16,884,459 shares. The 52-week range was USD 1.76 to USD 15.30, leaving the latest price 10.98 percent below the high.

The share move also needs to be read beside the broader trading picture. Iovance had gained 420.51 percent year to date in the Wall Street Journal market summary, while the latest session ended below the prior close.

Valuation and November date

Market capitalization stood at USD 6.2 billion as of October 16, 2026. The next scheduled corporate milestone is the November 5, 2026 release of third-quarter results, a date listed by The Wall Street Journal.

What the calendar adds

The November report will place the USD 99.31 million second-quarter revenue figure alongside the next update on commercial execution. Iovance develops tumor-infiltrating lymphocyte therapies, including Amtagvi, for patients with solid tumors, according to the company's investor overview.